# A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer

> **NCT01767857** · PHASE3 · TERMINATED · sponsor: **Janssen Research & Development, LLC** · enrollment: 643 (actual)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** Xilonix
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01767857
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-03-31
- **Primary completion:** 2017-06-30
- **Final completion:** 2017-06-30
- **Target enrollment:** 643 (ACTUAL)
- **Why stopped:** The study crossed the prospective futility boundary of primary endpoint
- **Last updated:** 2021-06-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01767857

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01767857, "A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01767857. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*